We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Intra-arterial Chemotherapy for Retinoblastoma—Reply ONLINE FIRST

Sameh E. Soliman, MD1; Brenda L. Gallie, MD1; Furqan Shaikh, MD1
[+] Author Affiliations
1Retinoblastoma Program, The Hospital for Sick Children, Toronto, Ontario, Canada
JAMA Ophthalmol. Published online August 11, 2016. doi:10.1001/jamaophthalmol.2016.2759
Text Size: A A A
Published online


In Reply We are happy that our systematic review1 raised important discussion on intra-arterial chemotherapy (IAC) for retinoblastoma. The development of IAC is clearly one of the most important recent advances in the management of children with retinoblastoma.

Abramson and colleagues asked why we rejected some articles based on judgment of scientific value, while including 2 patients from a social media survey.2 We excluded articles based on specified inclusion criteria rather than judgment. We included only 1 article from the Abramson group because we could not discern whether patients were duplicated across multiple publications. The patients from the social media survey were not included in our analyses or tables, but mentioned in our discussion. This is akin to postmarketing surveillance, allowable for crucially important outcomes such as death. There is no reason for us to believe that these deaths were untrue. However, they are not yet reported in any primary publication, supporting our statement that “retrospective studies are invariably subject to some selection and detection bias, risking underdetection.”1


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





August 11, 2016
Carol L. Shields, MD; Jerry A. Shields, MD
1Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania
JAMA Ophthalmol. Published online August 11, 2016.;():. doi:10.1001/jamaophthalmol.2016.2712.
August 11, 2016
David H. Abramson, MD; Brian P. Marr, MD; Jasmine H. Francis, MD
1Memorial Sloan-Kettering Cancer Center, New York, New York
JAMA Ophthalmol. Published online August 11, 2016.;():. doi:10.1001/jamaophthalmol.2016.2714.
August 11, 2016
Guillermo Chantada, MD, PhD; Paula Schaiquevich, PhD
1Hemato-Oncology Service, Hospital JP Garrahan, Buenos Aires, Argentina
2National Scientific and Technical Research Council, Buenos Aires, Argentina
JAMA Ophthalmol. Published online August 11, 2016.;():. doi:10.1001/jamaophthalmol.2016.2724.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...